Author(s):
Rajendran S.S., Neelaveni Thangavel, Angalaparameswari S., Anuyashika T., Nandhini S., Dhivith G., Karthick Saran P., Baarath A. K.
Email(s):
rajendran@rvsgroup.com
DOI:
10.52711/0974-4150.2026.00022 
Address:
Rajendran S.S.1*, Neelaveni Thangavel1, Angalaparameswari S.2, Anuyashika T.1, Nandhini S.1, Dhivith G.1, Karthick Saran P.1, Baarath A. K.1
1Department of Pharmaceutical Chemistry, RVS College of Pharmaceutical Sciences, Sulur, Coimbatore 641 402, Tamilnadu, India, Affiliated to The Tamil Nadu Dr MGR Medical University, Guindy, Chennai – 600032, Tamil Nadu, India.
2Department of Pharmaceutical Analysis, RVS College of Pharmaceutical Sciences, Sulur, Coimbatore 641 402, Tamilnadu, India, Affiliated to The Tamil Nadu Dr MGR Medical University, Guindy, Chennai – 600032, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 2,
Year - 2026
ABSTRACT:
Benzimidazole is a prominent nitrogen-containing heterocycle known for its broad utility across various fields, including agriculture, textile, and pharmaceuticals. Its unique electron rich structure and favorable chemical properties allow it to interact effectively with numerous biological targets. Benzimidazole derivatives are highly valuable due to their potential use in a broad spectrum of therapeutic treatments such as antimicrobial, antifungal, analgesic, antidiabetic, and anticancer treatments. Several drugs featuring the benzimidazole core, including Bilastine, Lerisetron, Maribavir, and Nocodazole, are already approved and used in clinical settings for indications such as allergies, viral infections, and cancer. Recently, anticancer agents like Binimetinib and Selumetinib—effective against BRAF-mutated melanoma and plexiform neurofibromas—have also received regulatory approval. Additionally, numerous benzimidazole-based candidates are currently undergoing advanced stages of clinical trials. Given the scaffold’s significant therapeutic promise, especially in oncology, it continues to attract the interest of medicinal chemists aiming to design novel, highly potent and target precise anticancer agents.
Cite this article:
Rajendran S.S., Neelaveni Thangavel, Angalaparameswari S., Anuyashika T., Nandhini S., Dhivith G., Karthick Saran P., Baarath A. K.. Targeting Cancer with Benzimidazole Derivatives: Emerging Trends and Future Directions. Asian Journal of Research in Chemistry.2026; 19(2):126-6. doi: 10.52711/0974-4150.2026.00022
Cite(Electronic):
Rajendran S.S., Neelaveni Thangavel, Angalaparameswari S., Anuyashika T., Nandhini S., Dhivith G., Karthick Saran P., Baarath A. K.. Targeting Cancer with Benzimidazole Derivatives: Emerging Trends and Future Directions. Asian Journal of Research in Chemistry.2026; 19(2):126-6. doi: 10.52711/0974-4150.2026.00022 Available on: https://ajrconline.org/AbstractView.aspx?PID=2026-19-2-9
4. REFERENCES:
1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021 Aug 15; 127(16): 3029-30.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2021 May; 71(3): 209-49.
3. Lipsick J. A history of cancer research: tumor suppressor genes. Cold Spring Harbor Perspectives in Biology. 2020 Feb 1; 12(2): a035907.
4. Rane JK, Frankell AM, Weeden CE, Swanton C. Clonal evolution in healthy and premalignant tissues: implications for early cancer interception strategies. Cancer Prevention Research. 2023 Jul 5; 16(7): 369-78.
5. Aguadé-Gorgorió G, Kauffman S, Solé R. Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity. Bull Math Biol. 2021 Dec 27;84(1):24. doi: 10.1007/s11538-021-00970-9. PMID: 34958403; PMCID: PMC8712307.
6. Ali I, Lone MN, Al-Othman ZA, Al-Warthan A, Sanagi MM. Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. Curr Drug Targets. 2015; 16(7): 711-34. doi: 10.2174/1389450116666150309115922. PMID: 25751009.
7. Sachdeva H, Khaturia S, Saquib M, Khatik N, Khandelwal AR, Meena R, Sharma K. Oxygen- and Sulphur-Containing Heterocyclic Compounds as Potential Anticancer Agents. Appl Biochem Biotechnol. 2022 Dec; 194(12): 6438-6467. doi: 10.1007/s12010-022-04099-w. Epub 2022 Jul 28. PMID: 35900713.
8. Chabner BA, Myers CE, Oliverio VT. Clinical pharmacology of anticancer drugs. Semin Oncol. 1977 Jun; 4(2): 165-91. PMID: 69319.
9. Nehra B, Mathew B, Chawla PA. A medicinal chemist’s perspective towards structure activity relationship of heterocycle based anticancer agents. Current Topics in Medicinal Chemistry. 2022 Mar 1;22(6):493-528.
10. Mushtaq A, Wu P, Naseer MM. Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets. Pharmacology & Therapeutics. 2024 Feb 1; 254: 108579.
11. Chung NT, Dung VC, Duc DX. Recent achievements in the synthesis of benzimidazole derivatives. RSC Advances. 2023; 13(46): 32734-71.
12. Farag B, Zaki ME, Elsayed DA, Gomha SM. Benzimidazole chemistry in oncology: recent developments in synthesis, activity, and SAR analysis. RSC Advances. 2025; 15(23): 18593-647.
13. Ibrahim AA, Said EG, AboulMagd AM, Amin NH, Abdel-Rahman HM. Synthesis and SARs of benzimidazoles: insights into antimicrobial innovation (2018–2024). RSC Advances. 2025; 15(27): 22097-127.
14. Tolomeu HV, Fraga CA. Imidazole: synthesis, functionalization and physicochemical properties of a privileged structure in medicinal chemistry. Molecules. 2023 Jan 13; 28(2): 838.
15. Kumar R, Marianesan AB, Pathak S. Benzimidazole as a Privileged Scaffold in Drug Design and Discovery. Current Topics in Medicinal Chemistry. 2024 Jul 1; 24(17): 1504-28.
16. Veerasamy R, Roy A, Karunakaran R, Rajak H. Structure–activity relationship analysis of benzimidazoles as emerging anti-inflammatory agents: An overview. Pharmaceuticals. 2021 Jul 11;14(7):663.
17. Ibrahim AA, Said EG, AboulMagd AM, Amin NH, Abdel-Rahman HM. Synthesis and SARs of benzimidazoles: insights into antimicrobial innovation (2018–2024). RSC Advances. 2025; 15(27): 22097-127.
18. Chen H, Mai Z, Jiang Z, Meng Y, Su S, Wu L, Zhang MZ, Manahelohe GM, Zhang W, Zhu Y. Antifungal Activity and Mechanism of Novel Benzimidazole-Containing Flavonol Derivatives as Potential Tubulin Polymerization Inhibitors against Botrytis cinerea. Journal of Agricultural and Food Chemistry. 2025 Jul 1.
19. Francesconi V, Rizzo M, Schenone S, Carbone A, Tonelli M. State-of-the-art review on the antiparasitic activity of benzimidazolebased derivatives: facing malaria, leishmaniasis, and trypanosomiasis. Current Medicinal Chemistry. 2024 May 1; 31(15): 1955-82.
20. Basaran R, Kilcigil G, Eke B. Evaluation of the Antioxidant Activity of Some Imines Containing 1H-Benzimidazoles/1H-Benzimidazol Iceren Bazi Iminlerin Antioksidan Aktivitesinin Degerlendirilmesi. Turkish Journal of Pharmaceutical Sciences. 2020 Dec 1; 17(6): 626-31
21. . Gaba M, Singh S, Mohan C. Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents. European Journal of Medicinal Chemistry. 2014 Apr 9; 76: 494-505.
22. Bano S, Nadeem H, Zulfiqar I, Shahzadi T, Anwar T, Bukhari A, Masaud SM. Synthesis and anti-inflammatory activity of benzimidazole derivatives; an in vitro, in vivo and in silico approach. Heliyon. 2024 May 15;10(9).
23. Noor A, Qazi NG, Nadeem H, Khan AU, Paracha RZ, Ali F, Saeed A. Synthesis, characterization, anti-ulcer action and molecular docking evaluation of novel benzimidazole-pyrazole hybrids. Chemistry Central Journal. 2017 Sep 2; 11(1): 85.
24. Kızılyıldırım S, Sucu B, Muhammed MT, Akkoç S, Esatbeyoglu T, Ozogul F. Experimental and theoretical studies on antituberculosis activity of different benzimidazole derivatives. Heliyon. 2025 Feb 28; 11(4).
25. Hernández-López H, Tejada-Rodríguez CJ, Leyva-Ramos S. A panoramic review of benzimidazole derivatives and their potential biological activity. Mini Reviews in Medicinal Chemistry. 2022 May 1;22(9):1268-80.
26. Tahlan S, Singh S, Pandey KC, Singh K. An Outline on Benzimidazole Containing Marketed Drugs with Proton Pump Inhibitor and H1 Receptor Antagonist Activities. Mini-Reviews in Medicinal Chemistry. 2025 Apr; 25(6): 440-62.
27. Bharadwaj SS, Poojary B, Nandish SK, Kengaiah J, Kirana MP, Shankar MK, Das AJ, Kulal A, Sannaningaiah D. Efficient synthesis and in silico studies of the benzimidazole hybrid scaffold with the quinolinyloxadiazole skeleton with potential α-glucosidase inhibitory, anticoagulant, and antiplatelet activities for type-II diabetes mellitus management and treating thrombotic disorders. ACS Omega. 2018 Oct 3; 3(10): 12562-74.
28. Lee YT, Tan YJ, Oon CE. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine. Acta Pharmaceutica Sinica B. 2023 Feb 1; 13(2): 478-97.
29. Tyagi YK, Jali G, Singh R. Synthesis and anti-cancer applications of benzimidazole derivatives-recent studies. Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents). 2022 Nov 1;22(19):3280-90.
30. Tahlan S, Kumar S, Kakkar S, Narasimhan B. Benzimidazole scaffolds as promising antiproliferative agents: A review. BMC Chemistry. 2019 May 15;13(1):66.
31. Monga J, Ghosh NS, Rani I, Singh R, Deswal G, Dhingra AK, Grewal AS. Unlocking the pharmacological potential of benzimidazole derivatives: a pathway to drug development. Current Topics in Medicinal Chemistry. 2024 Feb 1;24(5):437-85.
32. Imran M, Asdaq SM, Khan SA, Unnikrishnan Meenakshi D, Alamri AS, Alsanie WF, Alhomrani M, Mohzari Y, Alrashed A, AlMotairi M, Alkhaldi EH. Innovations and patent trends in the development of USFDA approved protein kinase inhibitors in the last two decades. Pharmaceuticals. 2021 Jul 22;14(8):710.
33. Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D’Avella C, Volpe M, Anderson E, Jones LM, Sun L. A phase II open-label trial of binimetinib and hydroxychloroquine in patients with advanced KRAS-mutant non-small cell lung cancer. The Oncologist. 2023 Jul 1;28(7):644-e564.
34. Fung AS, Graham DM, Chen EX, Stockley TL, Zhang T, Le LW, Albaba H, Pisters KM, Bradbury PA, Trinkaus M, Chan M. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer. 2021 Jul 1;157:21-9.
35. Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Bendamustine: A review of pharmacology, clinical use and immunological effects. Oncology Reports. 2022 Jun;47(6):114.
36. Bogeljić Patekar M, Milunović V, Mišura Jakobac K, Perica D, Mandac Rogulj I, Kursar M, Planinc-Peraica A, Ostojić Kolonić S. Bendamustine: an old drug in the new era for patients with non-hodgkin lymphomas and chronic lymphocytic leukemia. Acta Clinica Croatica. 2018 Sep 1;57(3.):542-53.
37. Gross AM, Glassberg B, Wolters PL, Dombi E, Baldwin A, Fisher MJ, Kim A, Bornhorst M, Weiss BD, Blakeley JO, Whitcomb P. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-oncology. 2022 Nov 1;24(11):1978-88.
38. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S. Selumetinib in children with inoperable plexiform neurofibromas. New England Journal of Medicine. 2020 Apr 9;382(15):1430-42.
39. Markham A, Keam SJ. Selumetinib: first approval. Drugs. 2020 Jun;80(9):931-7.
40. Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, Jiang Y, Liu Q, Xiong H. Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives. International Journal of Molecular Sciences. 2024 May 17;25(10):5489.
41. Torres-Guzmán R, Ganado MP, Mur C, Marugan C, Baquero C, Yang Y, Zeng Y, Bian H, Du J, de Dios A, Puig O. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Oncotarget. 2022 Jul 2;13:864.
42. Tolaney SM, Jhaveri K, Helsten T, Puhalla SL, Conlin A, Dees EC, Beeram M, Chapman SC, Lithio A, Litchfield LM, Goetz MP. Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. Frontiers in Oncology. 2025 Mar 12;15:1555921.
43. Masurkar PP, Prajapati P, Canedo J, Goswami S, Earl S, Bhattacharya K. Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis. Current Medical Research and Opinion. 2024 Oct 2;40(10):1753-67.
44. Hennes ER, Dow-Hillgartner EN, Bergsbaken JJ, Piccolo JK. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Journal of Oncology Pharmacy Practice. 2020 Apr; 26(3):718-29.
45. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Leath III CA, Cella D, Sun Z. Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. European Journal of Cancer. 2025 Jun 17:115587..
46. Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Poly (ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Database of Systematic Reviews. 2022 Feb 16; 2022(2):CD007929..
47. Porta C, Giglione P, Liguigli W, Paglino C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncology. 2015 Jan 31;11(1):39-50.
48. Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, Song HS, Shin DY, Lee HY, Kim HG, Lee KH. Phase II study of dovitinib in patients with castration-resistant prostate cancer (KCSG-GU11-05). Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2018 Jan 2;50(4):1252-9.
49. Schlichtig K, Dürr P, Dörje F, Fromm MF. New oral anti-cancer drugs and medication safety. Deutsches Ärzteblatt International. 2019 Nov 15;116(46):775.
50. Barnert AK, Hofmann P, Liekweg A, Kunze A, Scheid C, Hermes-Moll K, Osburg S, Jaehde U. Acceptance of an oncologic addendum for the application of the German Standardized Medication Plan in oral anticancer drug therapy. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2022 Nov 10;175:29-42.
51. San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019 Nov 14;11(11):1794.
52. Qin CH, Zhang SM, Huo XO, Song RP, Ling J. Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes. Oncology Letters. 2025 Mar 19;29(5):236.
53. Bastos DA, Antonarakis ES. Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Design, Development and Therapy. 2016 Jul 15:2289-97.
54. Xu Y, Liao S, Wang L, Wang Y, Wei W, Su K, Tu Y, Zhu S. Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin. Cancer Chemotherapy and Pharmacology. 2021 Jan;87(1):85-93.
55. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. Journal of Hematology & Oncology. 2021 Jul 8;14(1):108.
56. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. The Lancet Respiratory Medicine. 2020 Jun 1;8(6):561-72.
57. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017 Mar 30;8(23):38022.
58. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nature reviews Clinical Oncology. 2015 Aug;12(8):445-64.
59. Ahmed AA, Mohammed AF, Almarhoon ZM, Bräse S, Youssif BG. Design, synthesis, and apoptotic antiproliferative action of new benzimidazole/1, 2, 3-triazole hybrids as EGFR inhibitors. Frontiers in Chemistry. 2025 Jan 13;12:1541846.
60. Kumari S, Maddeboina K, Bachu RD, Boddu SH, Trippier PC, Tiwari AK. Pivotal role of nitrogen heterocycles in Alzheimer’s disease drug discovery. Drug Discovery Today. 2022 Oct 1;27(10):103322.
61. Nawaz F, Alam O, Perwez A, Rizvi MA, Naim MJ, Siddiqui N, Pottoo FH, Jha M. 3′‐(4‐(Benzyloxy) phenyl)‐1′‐phenyl‐5‐(heteroaryl/aryl)‐3, 4‐dihydro‐1′ H, 2H‐[3, 4′‐bipyrazole]‐2‐carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies. Archiv der Pharmazie. 2020 Apr;353(4):1900262.
62. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer. 2023 Feb 21;22(1):40.
63. Zhu X, Zhou W. The emerging regulation of VEGFR-2 in triple-negative breast cancer. Frontiers in Endocrinology. 2015 Oct 9;6:159.
64. Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, Khalifa MM. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022 Dec 31;37(1):403-16.
65. Natarajan R, Kumar P, Subramani A, Siraperuman A, Angamuthu P, Bhandare RR, Shaik AB. A critical review on therapeutic potential of benzimidazole derivatives: a privileged scaffold. Medicinal Chemistry. 2024 Mar 1;20(3):311-51.
66. de Castro Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry. 2014 Jan 7;71:1-4.
67. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J. A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors. Clinical Cancer Research. 2017 Oct 1; 23(19): 5981-92.
68. Kangussu-Marcolino MM, Singh U. Ponatinib, lestaurtinib, and mTOR/PI3K inhibitors are promising repurposing candidates against Entamoeba histolytica. Antimicrobial Agents and Chemotherapy. 2022 Feb 15;66(2):e01207-21.
69. Işık A, Çevik UA, Karayel A, Ahmad I, Patel H, Çelik İ, Gül ÜD, Bayazıt G, Bostancı HE, Koçak A, Özkay Y. Synthesis, DFT calculations, in silico studies, and antimicrobial evaluation of benzimidazole-thiadiazole derivatives. ACS Omega. 2024 Apr 9;9(16):18469.
70. Wu X, Xu Y, Liang Q, Yang X, Huang J, Wang J, Zhang H, Shi J. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Frontiers in Pharmacology. 2022 May 9;13:875372.
71. Singh S, Mandal MK, Masih A, Saha A, Ghosh SK, Bhat HR, Singh UP. 1, 3, 5‐Triazine: A versatile pharmacophore with diverse biological activities. Archiv der Pharmazie. 2021 Jun;354(6):2000363.
72. Shin Y, Suchomel J, Cardozo M, Duquette J, He X, Henne K, Hu YL, Kelly RC, McCarter J, McGee LR, Medina JC. Discovery, optimization, and in vivo evaluation of benzimidazole derivatives AM-8508 and AM-9635 as potent and selective PI3Kδ inhibitors. Journal of Medicinal Chemistry. 2016 Jan 14;59(1):431-47.
73. Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U. Design, Synthesis, and Development of Pyrazolo [1, 5-a] pyrimidine Derivatives as a Novel Series of Selective PI3K δ Inhibitors: Part II—Benzimidazole Derivatives. Pharmaceuticals. 2022 Jul 27;15(8):927.
74. Zeng M, Hu Y, Zhao L, Duan C, Wu H, Xu Y, Liu X, Wang Y, Jiang D, Zeng S. Design, synthesis, and pharmacological evaluation of triazine-based PI3K/mTOR inhibitors for the potential treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry. 2025 Feb 15;284:117200.
75. Garcia-Cuellar MP, Füller E, Mäthner E, Breitinger C, Hetzner K, Zeitlmann L, Borkhardt A, Slany RK. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Leukemia. 2014 Jul;28(7):1427-35.
76. Yadav U, Vanjari Y, Laxmikeshav K, Tokala R, Niggula PK, Kumar M, Talla V, Kamal A, Shankaraiah N. Synthesis and in vitro cytotoxicity evaluation of phenanthrene linked 2, 4-thiazolidinediones as potential anticancer agents. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2021 Jun 1;21(9):1127-40
77. Hamdi A, El-Shafey HW, Othman DI, El-Azab AS, AlSaif NA, Abdel-Aziz AA. Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies. Bioorganic Chemistry. 2022 May 1;122:105710.
78. Oniciuc L, Amăriucăi-Mantu D, Diaconu D, Mangalagiu V, Danac R, Antoci V, Mangalagiu II. Benzoquinoline derivatives: an attractive approach to newly small molecules with anticancer activity. International Journal of Molecular Sciences. 2023 May 1;24(9):8124.
79. Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 2022 Dec 31;37(1):1903-17.
80. Hamdi A, Elhusseiny WM, Othman DI, Haikal A, Bakheit AH, El-Azab AS, Al-Agamy MH, Abdel-Aziz AA. Synthesis, antitumor, and apoptosis-inducing activities of novel 5-arylidenethiazolidine-2, 4-dione derivatives: histone deacetylases inhibitory activity and molecular docking study. European Journal of Medicinal Chemistry. 2022 Dec 15;244:114827.
81. Marinescu M. Benzimidazole-triazole hybrids as antimicrobial and antiviral agents: A systematic review. Antibiotics. 2023 Jul 22;12(7):1220.